SPA
CGEM icon

Sherbrooke Park Advisers’s Cullinan Oncology CGEM Stock Holding History

Sherbrooke Park Advisers’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,976
Closed -$453K – 947
2024
Q2 		$453K Buy
+25,976
New +$553K 0.08% 458

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sherbrooke Park Advisers's CGEM Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Cullinan Oncology (CGEM) in Q3 2024, closing a stake of 25,976 shares — an estimated $453K sold.

Sherbrooke Park Advisers first reported a position in CGEM in Q2 2024 and held it in 1 quarter. The position peaked at $453K in Q2 2024. 137 funds tracked by Wall St. Rank hold CGEM as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining Cullinan Oncology position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 25,976 Cullinan Oncology shares in Q3 2024, an estimated $453K.
  • Sherbrooke Park Advisers first reported a position in Cullinan Oncology in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Cullinan Oncology position peaked at $453K in Q2 2024.
  • 137 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.